Weekly Digest – Mar 2024 Weekly Digest – Mar 2024 06 Mar 2024: Pfizer’s ADC inotuzumab ozogamicin gained FDA approval for use in pediatric patients with acute lymphoblastic leukemia The approval was based on data suggesting that Besponsa led to 42% […]
Weekly Digest – Mar 2024 Weekly Digest – Mar 2024 05 Mar 2024: Akari Therapeutics and Peak Bio merge to expand pipeline with Novel ADC Toolkit Akari Therapeutics and Peak Bio Inc. announced a merger to create Akari Therapeutics, Plc, […]
Weekly Digest – Mar 2024 Weekly Digest – Mar 2024 04 Mar 2024: EMA grants dual validation for Daiichi Sankyo and AstraZeneca’s Cancer ADC The European Medicines Agency (EMA) has validated the jointly developed TROP2-directed therapy, Dato-DXd, for patients with […]
Weekly Digest – Mar 2024 Weekly Digest – Mar 2024 29 Feb 2024: Gilead Partners with Abingworth, securing $210M, for Trodelvy trials to develop a Trop-2-directed ADC Gilead’s funding deal with VC shop Abingworth stands out as an unusual approach […]
